Myeloma Life Expectancy in the Elderly: What to Expect

Median survival for elderly patients diagnosed with multiple myeloma has roughly tripled over the past few decades, climbing from about 8 months in the mid-1970s to nearly 30 months for those diagnosed more recently, according to population-based data from the United States.¹ Those are averages, though, and they disguise enormous variation from person to person. What an individual can realistically expect depends less on the calendar year of diagnosis than on a handful of specific factors, some biological and some practical, that shape whether someone falls well above or well below the median.

How Much Survival Has Improved and Where It Stands Now

The most comprehensive look at elderly myeloma survival in the U.S. comes from an analysis of the SEER (Surveillance, Epidemiology, and End Results) cancer registry spanning 1975 through 2016. Over the entire period, the median relative survival for elderly patients was roughly 20 months, with about 60% alive at one year and 21% alive at five years. But those numbers are heavily dragged down by earlier decades when effective treatments barely existed. By 2013, one-year survival had risen to about 72%, and five-year survival had climbed to around 31%.¹ Those gains reflect the introduction of drugs that transformed myeloma treatment: proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Still, about two-thirds of elderly patients diagnosed today will not reach the five-year mark, which places myeloma among the more serious blood cancers for older adults.

Why Age Alone Is a Poor Predictor

Doctors increasingly recognize that a 72-year-old who walks three miles a day and manages no chronic conditions has a fundamentally different prognosis than a 72-year-old who needs help bathing and takes ten medications. That realization has pushed the field toward formal frailty scoring rather than relying on birthdate to guide treatment decisions. The International Myeloma Working Group (IMWG) frailty score, for instance, sorts patients 65 and older into fit, intermediate-fit, and frail categories based on age, functional ability, and other health problems.²

These categories carry real prognostic weight. In one trial of elderly patients receiving a proteasome-inhibitor-based regimen, frail patients had a median overall survival of about 37 months, while fit and intermediate-fit patients had not yet reached a median survival at the time of reporting, meaning the majority were still alive.³ A newer scoring tool, the Myeloma Elderly Prognostic Score (MEPS), integrates age 75 or older, kidney function, physical performance status, and the presence of ultra-high-risk chromosomal abnormalities into a single four-factor score, designed specifically for older patients who are not candidates for transplant.⁴ The practical takeaway is that your oncologist’s assessment of how your body is functioning overall tells you more about your likely trajectory than your age on paper.

The Factors That Move the Needle Most

Several measurable characteristics at diagnosis consistently predict how well or poorly an elderly patient will fare. Understanding them can help you have informed conversations with your care team.

Physical function: Patients with an ECOG performance status of 2 or worse, meaning they spend more than half their waking hours in bed or a chair, face substantially higher risks of both early death and disease progression.⁵
Disease stage: Patients diagnosed at a more advanced stage (ISS or R-ISS stage III) have a worse outlook than those caught earlier. In real-world data, both stage II and stage III disease were associated with roughly a 30-40% higher risk of progression or death compared to stage I.⁶
Kidney function: Myeloma often damages the kidneys, and how much the kidneys recover after treatment begins is a powerful predictor. In one study, patients whose kidney function improved after chemotherapy had a median survival of 28 months, compared with just 4 months for those whose kidneys did not recover.⁷
Chromosomal abnormalities: Certain genetic changes inside the myeloma cells, particularly deletions and translocations classified as high-risk, are linked to faster relapse and shorter survival. In real-world data, high-risk genetics were associated with about a 44% increase in the risk of progression or death.⁶ Elderly patients with these high-risk features have not benefited as much from modern treatment advances as others have.⁸

Early Death After Diagnosis

A reality that survival statistics can obscure is that a meaningful fraction of elderly patients die within the first few months. These early deaths skew the averages downward and represent a distinct clinical problem. A real-world analysis found that among patients 70 and older, the strongest predictors of early mortality were poor performance status and advanced disease stage.⁵ A separate study found that age 75 or older, stage III disease, and elevated lactate dehydrogenase (a marker of how aggressively the cancer is behaving) were the independent predictors, with infection being the most common cause of these early deaths, accounting for more than 60% of cases.⁹

This is worth understanding because it means that the patients who survive the first dangerous months often do considerably better than the raw median suggests. If you or a loved one has gotten through initial treatment without serious complications, your personal outlook is already better than the headline numbers.

What First-Line Treatment Can Achieve

For elderly patients who are not candidates for stem cell transplant, the current standard of care in many countries is a combination of daratumumab (a monoclonal antibody), lenalidomide, and dexamethasone, often called DRd. The landmark MAIA trial tested this regimen against lenalidomide and dexamethasone alone in newly diagnosed patients who were not eligible for transplant, with a median age of 73. At about two and a half years of follow-up, roughly 71% of patients receiving the daratumumab combination were alive without disease progression, compared with about 56% in the control group.¹⁰

With longer follow-up of about four and a half years, the benefit held: median progression-free survival had not yet been reached in the daratumumab group compared with about 34 months in the control group. The daratumumab regimen also reduced the risk of death by about a third.¹¹ These are encouraging numbers, though the trade-off is more side effects, particularly higher rates of low blood counts and pneumonia.

Stem Cell Transplant in Older Adults

Stem cell transplant has traditionally been reserved for younger patients, with an upper age limit often set around 65 to 70. That boundary is shifting. Several centers now evaluate transplant eligibility based on fitness rather than age alone. A retrospective analysis comparing patients over 70 with younger transplant recipients found no significant difference in overall survival or progression-free survival at 12 years, with both groups around 50%.¹²

A separate bi-centric analysis came to a similar conclusion, finding that transplant provided a survival benefit in both younger and selected elderly patients, and that advanced age alone should not disqualify someone from the procedure.¹³ The key word is “selected.” These are older patients who have been carefully vetted for adequate organ function, performance status, and ability to tolerate the intensive conditioning chemotherapy. Not every 72-year-old is a transplant candidate, but some are, and those who make it through the procedure seem to benefit as much as younger patients do.

When Myeloma Returns

Nearly all myeloma patients eventually relapse, and the question of what comes next is especially pressing for older adults whose bodies may not tolerate aggressive retreatment. Newer immunotherapies, including bispecific antibodies that target a protein called BCMA on myeloma cells, are now available for relapsed disease. A study of frail patients treated with these bispecific antibodies found outcomes comparable to younger and non-frail patients, supporting their use even in the population most likely to be excluded from aggressive treatment.¹⁴

Kidney problems, common in myeloma, do not appear to dramatically limit these newer approaches either. An analysis of patients with kidney impairment receiving either CAR-T cell therapy or bispecific antibodies found that kidney problems did not significantly increase mortality or shorten the time to the next treatment, though patients with kidney issues did experience more anemia and low platelet counts.¹⁵ This is meaningful for elderly patients, since kidney damage is both more common and harder to recover from in this age group.

Kidney Problems and Their Outsized Impact

The kidney deserves extra attention because it is one of the organs myeloma damages most, and kidney function at diagnosis is one of the strongest independent predictors of how long someone will live. The abnormal proteins produced by myeloma cells can clog the kidney’s filtering structures, and about a quarter of patients with kidney failure at diagnosis will see their kidney function recover with treatment.⁷ The survival difference between those who recover kidney function and those who do not is dramatic.

There is good news on this front. Since the introduction of newer myeloma drugs, survival for patients presenting with severe kidney impairment has improved substantially. Median survival in this group rose from roughly 18-19 months in the 1990s to about 29-32 months in the 2000s and beyond.¹⁶ That is still shorter than survival for patients without kidney problems, but the gap has narrowed.

Infections, Bone Disease, and Heart Risks

Myeloma weakens the immune system in multiple ways: the disease itself suppresses normal antibody production, and many treatments further depress immune function. Infections are a leading cause of death, especially in the first months after diagnosis. Current guidelines recommend vaccinating all myeloma patients against pneumonia, influenza, herpes zoster, and COVID-19, along with prophylactic antiviral medication to prevent herpes reactivation in patients receiving certain drug classes.¹⁷ Newer immunotherapies can cause especially prolonged immune suppression, raising the risk of viral reactivation and opportunistic infections beyond what older chemotherapy regimens caused.¹⁸

Bone disease affects most myeloma patients and can devastate quality of life through fractures, pain, and loss of mobility. Bone-modifying agents like bisphosphonates and denosumab reduce pain and fracture risk, though they do not rebuild bone that has already been destroyed and have not been clearly shown to extend overall survival.¹⁹ In a meta-analysis, denosumab was found to be comparable to zoledronic acid for preventing skeletal complications, with a better profile for kidney toxicity, making it a useful option for elderly patients whose kidneys are already compromised.²⁰

Heart problems round out the major complication picture. The proteasome inhibitor carfilzomib, commonly used in relapsed myeloma, carries a notable risk of heart failure. In a study of elderly patients receiving carfilzomib-based therapy, heart failure occurred in about a quarter of patients, with coronary artery disease, hypertension, kidney problems, and low albumin levels identified as the strongest risk factors.²¹ Blood clots are another concern: in older patients receiving lenalidomide or thalidomide-based regimens, the one-year incidence of venous blood clots was about 10%, and arterial events occurred in about 5%.²² Preventive blood thinners are standard with these medications, but elderly patients still need close monitoring.

Adjusting Treatment to the Patient

One of the most impactful trends in elderly myeloma care is dose adjustment guided by ongoing frailty assessment, rather than giving every patient the same regimen and waiting for side effects. Studies using dynamic frailty assessment, where the treatment team re-evaluates a patient’s fitness over time and adjusts drug doses accordingly, have found that this approach can reduce serious adverse reactions, drug discontinuation, and early death.²³ For families, this means that if your oncologist suggests lowering a dose or switching drugs because of how you are tolerating treatment, that decision is backed by evidence showing it leads to better outcomes overall, not worse ones.

Adherence to oral medications is another underappreciated factor. Many modern myeloma regimens include pills taken at home, sometimes on complex schedules, and elderly patients may struggle to keep track, especially if they are already managing multiple other medications. Clinicians are encouraged to pay attention to patients’ daily routines and involve family members in medication management, because poor adherence can undermine even the best regimen.²⁴

Quality of Life Beyond Survival Numbers

Survival statistics tell you nothing about how someone feels during those months and years. Myeloma patients at the time of diagnosis report lower quality of life compared with the general population across nearly every measure: physical function, emotional well-being, fatigue, pain, and social participation.²⁵ Treatment often improves many of these symptoms, particularly bone pain and fatigue, but the side effects of treatment can create new problems. For elderly patients, the calculus is especially delicate: an extra few months of survival may not be worth it if those months are spent dealing with debilitating side effects or repeated hospitalizations.

Early palliative care, which focuses on symptom management and quality of life rather than stopping treatment, appears to help. A retrospective study comparing myeloma patients who received early palliative care alongside standard hematologic treatment found significantly better quality-of-care indicators, reduced pain over time, and a trend toward less aggressive end-of-life interventions, with no reduction in overall survival.²⁶ The survival in both groups was about the same (around 5.3-5.5 years), which undercuts the common fear that palliative care means giving up. It means managing the disease more thoughtfully.

When Myeloma Is Found Before It Causes Symptoms

Some elderly patients first learn about an abnormal protein in their blood through routine lab work, before myeloma has caused any damage. These precursor conditions, called monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, progress to active myeloma at very different rates. MGUS progresses at about 1% per year, while smoldering myeloma progresses at roughly 10% per year for the first five years, then slows to about 3% per year for the next five, and eventually drops further.²⁷

For elderly patients with MGUS, the standard approach is periodic blood monitoring rather than treatment. Those with higher-risk smoldering myeloma are being studied in trials of early treatment, and initial results suggest that intervening before the disease causes organ damage may be beneficial, particularly if a comprehensive assessment of fitness is performed to ensure the patient can tolerate therapy.²⁸ The key point for older adults with these precursor conditions is that most will never develop active myeloma in their lifetime, so the monitoring-first approach is often the right call.

Disparities That Affect Who Benefits from Advances

Not all elderly patients have equal access to the treatments driving survival improvements. A large multi-institutional study found that Black patients with myeloma were significantly less likely to start treatment within 60 days of diagnosis, less likely to receive newer agents, and less likely to undergo stem cell transplant within the first year compared with White patients.²⁹ These disparities exist despite the fact that Black patients actually develop myeloma at roughly twice the rate and at younger ages. The survival improvements seen in clinical trials do not automatically translate to all populations in the real world, and structural barriers in access to specialty care, clinical trials, and transplant centers play a meaningful role.

Second Cancers During Long-Term Treatment

As myeloma patients live longer on continuous therapy, the risk of developing a second, unrelated cancer has drawn attention. Myeloma patients are at a slightly higher risk of second cancers compared with the general population. Patients over 65 consistently show a higher risk, with one large analysis finding a standardized incidence ratio of about 1.29.³⁰ Much of the concern has centered on lenalidomide, a drug used for long-term maintenance. One study in the Myeloma XI trial found that transplant-ineligible patients over 74 receiving lenalidomide maintenance had a second cancer rate of about 17%, compared with roughly 10% in those under 74.³¹

However, a population-based study of older Medicare beneficiaries found that first-line lenalidomide was not associated with a significantly increased risk of second cancers compared with other treatments, with five-year rates of about 5% versus 4%.³² The risk, while real, needs to be weighed against the substantial survival benefit of continued treatment. For most elderly patients, the gain from staying on effective therapy far outweighs the modest increase in second cancer risk.

Hospice and End-of-Life Planning

Because myeloma remains incurable, end-of-life planning eventually becomes relevant for most patients. A large study of older myeloma patients found that hospice enrollment nearly doubled between 2000 and 2013, with almost half of patients enrolling in hospice before death. About 17% enrolled within just three days of death, though the rate of this very late enrollment did not increase over the study period, suggesting that the growth in hospice use reflected genuinely earlier, more meaningful engagement rather than last-minute referrals.³³ Patients who enrolled in hospice had substantially lower odds of receiving aggressive medical interventions in their final month of life.

Palliative care consultation, ideally beginning more than 30 days before death, was associated with fewer hospitalizations in the final month and longer hospice stays in a study of myeloma patients, while consultations that came very late or not at all were associated with more aggressive and potentially unwanted care near the end.³⁴ For families navigating this, the evidence consistently says: earlier conversations about goals of care lead to better experiences, not shorter lives.